{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:02Z","timestamp":1792813502198,"version":"4.5.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["101575"],"award-info":[{"award-number":["101575"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["109056"],"award-info":[{"award-number":["109056"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["64787"],"award-info":[{"award-number":["64787"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["85858"],"award-info":[{"award-number":["85858"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013372","name":"Newcastle University | Wellcome Trust Centre for Mitochondrial Research","doi-asserted-by":"publisher","award":["098316"],"award-info":[{"award-number":["098316"]}],"id":[{"id":"10.13039\/501100013372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013372","name":"Newcastle University | Wellcome Trust Centre for Mitochondrial Research","doi-asserted-by":"publisher","award":["203135"],"award-info":[{"award-number":["203135"]}],"id":[{"id":"10.13039\/501100013372","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:p>Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis. QT prolongation, which is associated with fatal cardiac arrhythmias, is caused by several antitubercular drugs, including clofazimine, but there are no data quantifying the effect of clofazimine concentration on QT prolongation.<\/jats:p>","DOI":"10.1128\/aac.02687-20","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T14:34:16Z","timestamp":1618583656000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2134-8749","authenticated-orcid":true,"given":"Mahmoud Tareq","family":"Abdelwahab","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Court","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Everitt","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stellenbosch University, Tygerberg, South Africa"},{"name":"Task Applied Science, Bellville, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin M.","family":"Svensson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Department of Pharmacy, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-6606","authenticated-orcid":true,"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"},{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-079X","authenticated-orcid":true,"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment.","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. 2020. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw426"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa310"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00239-17"},{"key":"e_1_3_3_6_2","first-page":"63","article-title":"Clofazimine induced cardiotoxicity-a case report","volume":"66","author":"Choudhri S","year":"1995","unstructured":"Choudhri S, Harris L, Butany J, Keystone J. 1995. Clofazimine induced cardiotoxicity-a case report. Lepr Rev 66:63\u201368.","journal-title":"Lepr Rev"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01207-2016"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1801OC"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125317721662"},{"key":"e_1_3_3_10_2","first-page":"523","article-title":"Drug induced QT prolongation","volume":"14","author":"Zareba W","year":"2007","unstructured":"Zareba W. 2007. Drug induced QT prolongation. Cardiol J 14:523\u2013533.","journal-title":"Cardiol J"},{"key":"e_1_3_3_11_2","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Dannemann B","year":"2012","unstructured":"Dannemann B, Bakare N, De Marez T, Lounis N, van Heeswijk R, Meyvisch P, Haxaire-Theeuwes M, Andries K, Everitt D, Upton A. 2012. QTcF prolongation in a Phase II trial of TMC207 plus background regimen as treatment for multidrug-resistant tuberculosis: effect of co-administration with clofazimine. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9829-2"},{"key":"e_1_3_3_13_2","unstructured":"ICH. 2005. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002879.pdf."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-014-0040-1"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30426-0"},{"key":"e_1_3_3_16_2","unstructured":"Novartis Pharma. 2019. Lamprene (clofazimine) capsules: highlights of prescribing information. Novartis Pharmaceuticals Corporation East Hanover NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/019500s014lbl.pdf."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-0736(97)80005-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1098\/rsta.2008.0231"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0736-1"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070363"},{"key":"e_1_3_3_21_2","volume-title":"The 14th Annual Meeting Population Approach Group Europe (PAGE)","author":"Holfrod N","year":"2005","unstructured":"Holfrod N. 2005. The visual predictive check\u2014superiority to standard diagnostic (Rorschach) plot. The 14th Annual Meeting Population Approach Group Europe (PAGE), Pamplona, Spain."},{"key":"e_1_3_3_22_2","volume-title":"NONMEM 7.4 users guides (1989\u20132019).","author":"Beal S","year":"2019","unstructured":"Beal S, Sheiner L, Boeckmann A, Bauer RJ. 2019. NONMEM 7.4 users guides (1989\u20132019). ICON plc, Gaithersburg, MD. https:\/\/nonmem.iconplc.com\/nonmem744."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02687-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02687-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:11:36Z","timestamp":1645485096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02687-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["10.1128\/AAC.02687-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.02687-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2020-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02687-20"}}